Pangaea Oncology S.A. (PANG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pangaea Oncology S.A. (PANG) has a cash flow conversion efficiency ratio of -0.057x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.25 Million ≈ $-1.47 Million USD) by net assets (€22.06 Million ≈ $25.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Pangaea Oncology S.A. for the company's overall valuation and market capitalisation.
Pangaea Oncology S.A. - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Pangaea Oncology S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pangaea Oncology S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pangaea Oncology S.A. ranked by their cash flow conversion efficiency. Explore PANG operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
5E ADVANCED MATLS NEW
F:J9I1
|
-0.101x |
|
Zomedica Pharmaceuticals Corp
NYSE MKT:ZOM
|
-0.050x |
|
FLUOGUIDE A/S DK -1
F:96X
|
-0.092x |
|
Unifosa
TWO:8277
|
0.064x |
|
Hotelim Société Anonyme
PA:MLHOT
|
N/A |
|
Donkeyrepublic Holding AS
CO:DONKEY
|
0.036x |
|
Covalon Technologies Ltd.
V:COV
|
0.218x |
|
LightInTheBox Holding Co Ltd ARD
NYSE:LITB
|
-2.224x |
Annual Cash Flow Conversion Efficiency for Pangaea Oncology S.A. (2013–2025)
The table below shows the annual cash flow conversion efficiency of Pangaea Oncology S.A. from 2013 to 2025. View today's stock price for Pangaea Oncology S.A. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €22.06 Million ≈ $25.79 Million |
€-2.52 Million ≈ $-2.95 Million |
-0.114x | +42.85% |
| 2024-12-31 | €22.84 Million ≈ $26.70 Million |
€-4.57 Million ≈ $-5.34 Million |
-0.200x | -56.82% |
| 2023-12-31 | €18.81 Million ≈ $21.99 Million |
€-2.40 Million ≈ $-2.80 Million |
-0.127x | +19.97% |
| 2022-12-31 | €23.08 Million ≈ $26.98 Million |
€-3.68 Million ≈ $-4.30 Million |
-0.159x | +10.27% |
| 2021-12-31 | €14.09 Million ≈ $16.47 Million |
€-2.50 Million ≈ $-2.92 Million |
-0.178x | +20.60% |
| 2020-12-31 | €8.57 Million ≈ $10.01 Million |
€-1.92 Million ≈ $-2.24 Million |
-0.224x | +22.45% |
| 2019-12-31 | €8.31 Million ≈ $9.72 Million |
€-2.40 Million ≈ $-2.80 Million |
-0.288x | -14.68% |
| 2018-12-31 | €8.62 Million ≈ $10.07 Million |
€-2.17 Million ≈ $-2.53 Million |
-0.251x | +80.42% |
| 2017-12-31 | €5.05 Million ≈ $5.90 Million |
€-6.48 Million ≈ $-7.58 Million |
-1.284x | -336.22% |
| 2016-12-31 | €6.05 Million ≈ $7.07 Million |
€-1.78 Million ≈ $-2.08 Million |
-0.294x | +86.59% |
| 2015-12-31 | €1.05 Million ≈ $1.23 Million |
€-2.31 Million ≈ $-2.70 Million |
-2.194x | -88.79% |
| 2014-12-31 | €1.63 Million ≈ $1.90 Million |
€-1.89 Million ≈ $-2.21 Million |
-1.162x | -221.80% |
| 2013-12-31 | €1.83 Million ≈ $2.14 Million |
€-659.69K ≈ $-771.25K |
-0.361x | -- |
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling a… Read more